0001628280-23-036466.txt : 20231102
0001628280-23-036466.hdr.sgml : 20231102
20231102170056
ACCESSION NUMBER: 0001628280-23-036466
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231031
FILED AS OF DATE: 20231102
DATE AS OF CHANGE: 20231102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Baldry Mark
CENTRAL INDEX KEY: 0001644137
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 231373406
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
wk-form4_1698958841.xml
FORM 4
X0508
4
2023-10-31
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001644137
Baldry Mark
C/O X4 PHARMACEUTICALS, INC.
61 NORTH BEACON STREET 4TH FLOOR
BOSTON
MA
02134
0
1
0
0
Chief Commercial Officer
0
Common Stock
2023-10-31
4
A
0
34947
0
A
34947
D
Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.
/s/ Adam S. Mostafa, attorney-in-fact
2023-11-02